StockData
Citius Oncology, Inc. logo

Citius Oncology, Inc. (CTOR) stock

CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$0.55+0.01 (+2.36%)

Close on Nov 17, 2026Market cap $50.92MP/E –Yield –

Citius Oncology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Citius Oncology's operating income for the twelve months ending Jun 30, 2026 was -$47.29M. For fiscal 2025 it was -$23.52M.

Annual operating income

PeriodPeriod endValueChange
FY2025Sep 30, 2025-$23.52M–
FY2022Dec 31, 2022-$138.12K–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$8.72M–
Q2 FY2026CQ1 2026Mar 31, 2026-$28.61M–
Q1 FY2026CQ4 2025Dec 31, 2025-$5.25M–
Q4 FY2025CQ3 2025Sep 30, 2025-$4.71M–
Q3 FY2025CQ2 2025Jun 30, 2025-$4.94M–
Q2 FY2025CQ1 2025Mar 31, 2025-$7.47M–
Q1 FY2025CQ4 2024Dec 31, 2024-$6.39M–

More Citius Oncology figures

See a number that looks wrong?